Generation Bio Co. (NASDAQ:GBIO – Get Rating) Director Charles A. Rowland, Jr. purchased 17,147 shares of the firm’s stock in a transaction that occurred on Thursday, September 15th. The stock was acquired at an average price of $5.41 per share, for a total transaction of $92,765.27. Following the completion of the purchase, the director now owns 142,566 shares of the company’s stock, valued at $771,282.06. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Generation Bio Stock Performance
Shares of GBIO stock opened at $5.21 on Tuesday. The stock has a fifty day moving average price of $6.37 and a 200 day moving average price of $6.39. The stock has a market cap of $307.45 million, a PE ratio of -2.20 and a beta of 1.96. Generation Bio Co. has a 1 year low of $3.96 and a 1 year high of $26.70.
Generation Bio (NASDAQ:GBIO – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.03). As a group, equities research analysts predict that Generation Bio Co. will post -2.63 earnings per share for the current year.
Hedge Funds Weigh In On Generation Bio
Analysts Set New Price Targets
A number of research firms recently weighed in on GBIO. JMP Securities lifted their price target on Generation Bio from $10.00 to $11.00 and gave the company a “market outperform” rating in a research note on Monday, August 8th. Wedbush restated an “outperform” rating and issued a $24.00 price target on shares of Generation Bio in a research note on Friday, August 5th. Finally, Needham & Company LLC decreased their price target on Generation Bio from $27.00 to $23.00 and set a “buy” rating on the stock in a research note on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.
Generation Bio Company Profile
Generation Bio Co, a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
- Get a free copy of the StockNews.com research report on Generation Bio (GBIO)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.